Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
On January 6, 2022, Ayala Pharmaceuticals (Nasdaq: AYLA) announced its participation at the H.C. Wainwright BioConnect Virtual Conference, scheduled for January 10-13, 2022. The company, focused on small molecule therapeutics for rare and aggressive cancers, has two key candidates: AL101 and AL102. AL101 is in Phase 2 trials for Adenoid Cystic Carcinoma and Triple Negative Breast Cancer, while AL102 is in pivotal Phase 2/3 trials for desmoid tumors. The presentation will be available via webcast starting January 10, 2022, at 7:00 AM ET on Ayala's website.
- None.
- None.
REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.
A webcast of the presentation will be available on the “Events and Presentations” section of the Ayala Pharmaceuticals website, beginning at 7:00 AM ET on Monday, January 10, 2022.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.
Contacts:
Investors:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com
FAQ
What is the date of the H.C. Wainwright BioConnect Virtual Conference for Ayala Pharmaceuticals?
Where can I watch Ayala Pharmaceuticals' presentation during the conference?
What are the main focuses of Ayala Pharmaceuticals?
What clinical trials are currently underway for Ayala Pharmaceuticals' product candidates?
What types of cancers are targeted by Ayala Pharmaceuticals' AL101 and AL102?
